Braun Stacey Associates Inc. cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,146 shares of the biopharmaceutical company's stock after selling 1,172 shares during the period. Braun Stacey Associates Inc.'s holdings in Regeneron Pharmaceuticals were worth $23,281,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of REGN. GLOBALT Investments LLC GA grew its holdings in shares of Regeneron Pharmaceuticals by 1.5% in the third quarter. GLOBALT Investments LLC GA now owns 1,067 shares of the biopharmaceutical company's stock worth $1,122,000 after acquiring an additional 16 shares during the period. Quest Partners LLC lifted its stake in shares of Regeneron Pharmaceuticals by 391.0% in the 3rd quarter. Quest Partners LLC now owns 1,974 shares of the biopharmaceutical company's stock worth $2,075,000 after purchasing an additional 1,572 shares during the period. AMG National Trust Bank boosted its holdings in shares of Regeneron Pharmaceuticals by 14.6% in the third quarter. AMG National Trust Bank now owns 220 shares of the biopharmaceutical company's stock worth $231,000 after buying an additional 28 shares during the last quarter. Swiss National Bank increased its holdings in Regeneron Pharmaceuticals by 0.6% during the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company's stock valued at $338,079,000 after buying an additional 2,000 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its position in Regeneron Pharmaceuticals by 16.7% in the third quarter. Thrivent Financial for Lutherans now owns 9,120 shares of the biopharmaceutical company's stock worth $9,587,000 after acquiring an additional 1,306 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.
Insiders Place Their Bets
In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm's stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company's stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.48% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on REGN shares. StockNews.com cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a research note on Thursday, October 24th. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a "buy" rating in a research report on Tuesday, July 23rd. Finally, Leerink Partners restated a "market perform" rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $1,099.55.
Read Our Latest Stock Report on REGN
Regeneron Pharmaceuticals Stock Up 0.2 %
Shares of Regeneron Pharmaceuticals stock traded up $1.15 on Monday, reaching $757.96. The stock had a trading volume of 448,723 shares, compared to its average volume of 530,091. The company has a 50 day moving average price of $985.21 and a 200 day moving average price of $1,034.89. The stock has a market capitalization of $83.29 billion, a P/E ratio of 18.73, a P/E/G ratio of 2.86 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $750.20 and a 1 year high of $1,211.20.
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
See Also
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
